Pss16 - Cost Per Responder Analysis of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Versus Non-Biologic Systemic Therapy in the Treatment of Moderate to Severe Plaque Psoriasis

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2516
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam for Scalp Psoriasis

Clinical, Cosmetic and Investigational Dermatology
Dermatology
2019English

Erratum To: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients With Moderate-To-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study

American Journal of Clinical Dermatology
DermatologyMedicine
2017English

Vasoconstrictor Potencey of Fixed Combination Calcipotriol Plus Betamethasone Dipropionate Foam Versus Other Corticosteroid Psoriasis Treatments

SKIN The Journal of Cutaneous Medicine
2018English

Cost Per Responder for Ixekizumab and Other Biologic Drugs Approved for the Treatment of Moderate-To-Severe Plaque Psoriasis in Italy

Global and Regional Health Technology Assessment
Health Policy
2019English

New Calcipotriol/Betamethasone Dipropionate Foam Formulation for the Treatment of Psoriasis: An Overview

Revista da Sociedade Portuguesa de Dermatologia e Venereologia
2018English

Pss17 - Cost Per Responder Analysis of Brodalumab Compared With Ustekinumab in the Treatment of Moderate-To-Severe Plaque Psoriasis in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Calcipotriol Plus Betamethasone Versus Betamethasone in Treatment of Scalp Psoriasis in an Iranian Population

Journal of Skin and Stem Cell
2016English

Pss33 - Secukinumab as First Biologic Treatment: A Cost Per Responder Analysis Compared With Licensed Biologics, for Moderate to Severe Psoriasis in Argentina

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss31 - Cost Per Responder of Secukinumab Compared to Other Biologics in Moderate-To-Severe Plaque Psoriasis From the Private Payer Perspective in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy